Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Why It Matters

The results signal Coherus’ successful transition from a biosimilars player to an innovative oncology firm with a growing revenue base and a pipeline poised to generate future growth.

Key Takeaways

• LOQTORZI Q4 revenue $12.4M, 64% YoY increase
• Debt cut over 90% to $38.8M, improving balance sheet
• Tagmokitug entering multiple Phase 1b combos, data 2026
• Casdozokitug shows 17% complete responses in HCC Phase 2
• $55M raised in 2025‑26 equity offerings, boosting cash to $172M

Pulse Analysis

Coherus Oncology’s FY 2025 financials illustrate a turning point for the Redwood City‑based company. Revenue climbed to $42.2 million, propelled by LOQTORZI’s strong uptake in nasopharyngeal carcinoma, while operating losses narrowed as SG&A expenses fell and cash on hand surged past $170 million. The dramatic debt reduction—over 90% since its 2024 peak—enhances financial flexibility, allowing the firm to fund its expanding clinical agenda without over‑reliance on external financing.

LOQTORZI remains the sole FDA‑approved PD‑1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma, a market estimated at $250 million in the United States. Recent six‑year overall‑survival data from the Phase 3 JUPITER‑02 trial showed a median OS of 64.8 months versus 33.7 months with chemotherapy alone, delivering a 38% mortality risk reduction. These outcomes not only reinforce LOQTORZI’s clinical value proposition but also position Coherus to pursue label extensions and combination regimens that could capture additional market share amid intensifying competition from larger immuno‑oncology players.

Beyond its flagship product, Coherus is betting on two differentiated biologics. Tagmokitug, a CCR8‑targeted cytolytic antibody, aims to deplete tumor‑resident regulatory T cells and is slated for combination studies with toripalimab, chemotherapy, and J&J’s T‑cell engager pasritamig across several solid‑tumor indications, with readouts expected in 2026. Meanwhile, Casdozokitug, an IL‑27 antagonist, delivered a 17% complete response rate in a Phase 2 hepatocellular carcinoma cohort, suggesting a novel mechanism to overcome immune resistance. Successful data could unlock partnership opportunities and broaden Coherus’ revenue streams, making the company a more compelling prospect for investors seeking exposure to next‑generation immuno‑oncology therapies.